Germany latest country to suspend generics following GVK Biosciences concerns
The German regulator BfArM has suspended drugs including some produced by Dr Reddy’s (NSE: DRREDDY), Mylan (Nasdaq: MYL) and Stada Arzneimittel over concerns about clinical trials conducted by GVK Biosciences.
Trials carried out at the company’s site in Hyderabad, India, have triggered safety concerns in multiple products, and authorities in France, Germany, Belgium and Luxembourg have suspended approval of 25 drugs on this basis. Concerns are based on anomalies found in electrocardiograms in bioequivalence studies.
Generic versions of Bristol-Myers Squibb (NYSE: BMY) and Sanofi’s (Euronext: SAN) Plavix (clopidogrel) and AstraZeneca’s (LSE: AZN) Nexium (esomeprazole) have been affected by the suspension. Drug manufacturers, wholesale dealers, medical stores and other outlets have been ordered to suspend the drugs, though BfArM have assured that this will not lead to shortages.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze